MARKET

MGTX

MGTX

MeiraGTx Holdings plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.40
-0.44
-2.97%
Closed 16:00 06/01 EDT
OPEN
14.62
PREV CLOSE
14.84
HIGH
15.19
LOW
14.32
VOLUME
140.84K
TURNOVER
--
52 WEEK HIGH
30.23
52 WEEK LOW
8.82
MARKET CAP
538.02M
P/E (TTM)
-9.5037
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MGTX stock price target is 35.25 with a high estimate of 45.00 and a low estimate of 24.00.

EPS

MGTX News

More
MeiraGTx Announces Move to Virtual-Only Format for 2020 Annual General Meeting of Shareholders
LONDON and NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced that its 2020 Annual General Meeting of Shareholders scheduled for Tuesday, June 2, 2020 at 10:0
GlobeNewswire · 6d ago
MeiraGTx Holdings Q1 EPS $(0.430) Up From $(0.620) YoY
MeiraGTx Holdings (NASDAQ:MGTX) reported quarterly losses of $(0.430) per share. This is a 30.65 percent increase over losses of $(0.620) per share from the same period last year.
Benzinga · 05/07 21:23
MeiraGTx Reports First Quarter 2020 Financial Results
LONDON and NEW YORK, May 07, 2020 -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial.
GlobeNewswire · 05/07 20:30
MeiraGTx to Present at the Virtual Bank of America Securities 2020 Health Care Conference
LONDON and NEW YORK, May 06, 2020 -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced.
GlobeNewswire · 05/06 20:30
Week 17 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
Seeking Alpha - Article · 04/19 09:54
MeiraGTx: An Exciting Gene Therapy Pick In March 2020
Seeking Alpha - Article · 03/24 17:29
Abeona Treats First Patient in Pivotal Gene Therapy Study
Zacks · 03/18 14:10
MeiraGTx Holdings (MGTX) Presents At Cowen and Comapny 40th Annual Health Care Conference - Slideshow
Seeking Alpha - Article · 03/17 21:39

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About MGTX

MeiraGTx Holdings plc is a clinical-stage therapy company. The Company develops gene therapy treatments for a range of inherited and acquired disorders. It is focused on developing therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia, radiation treatment for head and neck cancers and neurodegenerative diseases, such as amyothrophic lateral sclerosis (ALS). It is also developing transformative technology to enable the use of small molecules to turn gene therapy product candidates on and off. It is focused on three areas of unmet medical needs, including inherited retinal diseases, severe forms of xerostomia and neurodegenerative diseases. Its product candidates include AAV-CNGB3, AAV-CNGA3, AAV-RPGR, AAV-RPE65, A006, AAV-AQP1 and AAV-UPF1.
More

Webull offers kinds of MeiraGTx Holdings PLC stock information, including NASDAQ:MGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGTX stock news, and many more online research tools to help you make informed decisions.